These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 29140271)

  • 21. How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
    Milik SN; Lasheen DS; Serya RAT; Abouzid KAM
    Eur J Med Chem; 2017 Dec; 142():131-151. PubMed ID: 28754471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of resistance to EGFR targeted therapies.
    Hrustanovic G; Lee BJ; Bivona TG
    Cancer Biol Ther; 2013 Apr; 14(4):304-14. PubMed ID: 23358468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
    Bianco R; Damiano V; Gelardi T; Daniele G; Ciardiello F; Tortora G
    Curr Pharm Des; 2007; 13(33):3358-67. PubMed ID: 18045190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
    Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR-targeted therapies in the post-genomic era.
    Xu MJ; Johnson DE; Grandis JR
    Cancer Metastasis Rev; 2017 Sep; 36(3):463-473. PubMed ID: 28866730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma.
    Kao J; Sikora AT; Fu S
    Curr Cancer Drug Targets; 2009 Dec; 9(8):931-7. PubMed ID: 20025602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.
    Juergens RA; Bratman SV; Tsao MS; Laurie SA; Sara Kuruvilla M; Razak AR; Hansen AR
    Cancer Treat Rev; 2017 Mar; 54():43-57. PubMed ID: 28192747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
    Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
    Morgillo F; Bareschino MA; Bianco R; Tortora G; Ciardiello F
    Differentiation; 2007 Nov; 75(9):788-99. PubMed ID: 17608727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
    De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
    Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR and NF-κB: partners in cancer.
    Shostak K; Chariot A
    Trends Mol Med; 2015 Jun; 21(6):385-93. PubMed ID: 25979753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer.
    Dienstmann R; De Dosso S; Felip E; Tabernero J
    Mol Oncol; 2012 Feb; 6(1):15-26. PubMed ID: 22189054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Zibelman M; Mehra R
    Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer.
    Husain H; Scur M; Murtuza A; Bui N; Woodward B; Kurzrock R
    Mol Cancer Ther; 2017 Feb; 16(2):265-272. PubMed ID: 28159915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR-TKIs resistance via EGFR-independent signaling pathways.
    Liu Q; Yu S; Zhao W; Qin S; Chu Q; Wu K
    Mol Cancer; 2018 Feb; 17(1):53. PubMed ID: 29455669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging paradigms and recent progress in targeting ErbB in cancers.
    Stoup N; Liberelle M; Lebègue N; Van Seuningen I
    Trends Pharmacol Sci; 2024 Jun; 45(6):552-576. PubMed ID: 38797570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.